300 related articles for article (PubMed ID: 32985499)
1. Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma.
Yang Z; Xu J; Li L; Li R; Wang Y; Tian Y; Guo W; Wang Z; Tan F; Ying J; Jiao Y; Gao S; Wang J; Gao Y; He J
Nat Commun; 2020 Sep; 11(1):4878. PubMed ID: 32985499
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
3. Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies.
Stephan-Falkenau S; Streubel A; Mairinger T; Blum TG; Kollmeier J; Mairinger FD; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445733
[TBL] [Abstract][Full Text] [Related]
4.
Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
[TBL] [Abstract][Full Text] [Related]
5. An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic Option.
Manzotti G; Torricelli F; Benedetta D; Lococo F; Sancisi V; Rossi G; Piana S; Ciarrocchi A
Clin Cancer Res; 2019 Apr; 25(7):2348-2360. PubMed ID: 30587547
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
Jiao Y; Liu M; Luo N; Guo H; Li J
Oral Oncol; 2021 Jan; 112():104992. PubMed ID: 32943323
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
8. The EMT transcription factor, Twist1, as a novel therapeutic target for pulmonary sarcomatoid carcinomas.
Liu T; Zhao X; Zheng X; Zheng Y; Dong X; Zhao N; Liao S; Sun B
Int J Oncol; 2020 Mar; 56(3):750-760. PubMed ID: 32124963
[TBL] [Abstract][Full Text] [Related]
9. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
[TBL] [Abstract][Full Text] [Related]
10. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
[TBL] [Abstract][Full Text] [Related]
11. PSC subtyping based on TTF-1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies.
Yang Z; Tian H; Li L; Li C; Xu J; Bie F; Chen Y; Tian Y; Bai G; Peng Y; Yang J; Fan T; Xiao C; Liu W; Liu L; Li R; Sun S; Zheng B; Tan F; Ying J; Li C; Gao S; He J
Int J Cancer; 2022 Sep; 151(5):717-729. PubMed ID: 35612583
[TBL] [Abstract][Full Text] [Related]
12. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
[TBL] [Abstract][Full Text] [Related]
14. Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8
Zhang C; Li Z; Zhang Y; Zhao C; Wang H; Lin J; Liu C; Wang X; Wang H
Int J Gen Med; 2022; 15():4209-4220. PubMed ID: 35480996
[TBL] [Abstract][Full Text] [Related]
15. The Correlation Between Histologic, Immunophenotypic, and Molecular Characteristics of Pulmonary Sarcomatoid Carcinoma Reveals That Sarcomatoid Change Is Potentially Derived From Epithelial Carcinoma Cells Undergoing Epithelial-Mesenchymal Transition.
Huang Y; Guo J; Li S; Liu J; Xu J; Ye W; Zhang L; Dong Z; Wu W; Wu C; Hou L
Appl Immunohistochem Mol Morphol; 2023 Jan; 31(1):17-25. PubMed ID: 36165833
[TBL] [Abstract][Full Text] [Related]
16. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
Lin SH; Wang J; Saintigny P; Wu CC; Giri U; Zhang J; Menju T; Diao L; Byers L; Weinstein JN; Coombes KR; Girard L; Komaki R; Wistuba II; Date H; Minna JD; Heymach JV
BMC Genomics; 2014 Dec; 15(1):1079. PubMed ID: 25486910
[TBL] [Abstract][Full Text] [Related]
17. The treatment of advanced pulmonary sarcomatoid carcinoma.
Zheng Y; Fu Y; Zhong Q; Deng R; Zhang Y
Future Oncol; 2022 Feb; 18(6):727-738. PubMed ID: 34879738
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma.
Sim JK; Chung SM; Choi JH; Oh JY; Lee SH; Kim JH; Min KH; Hur GY; Shim JJ; Kang KH; Shin BK; Lee JH; Lee SY
Korean J Intern Med; 2018 Jul; 33(4):737-744. PubMed ID: 29458244
[TBL] [Abstract][Full Text] [Related]
19. Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas.
Qin J; Chen B; Li C; Yan J; Lu H
Cancer Genet; 2021 Jan; 250-251():12-19. PubMed ID: 33217678
[TBL] [Abstract][Full Text] [Related]
20. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.
Lee WC; Diao L; Wang J; Zhang J; Roarty EB; Varghese S; Chow CW; Fujimoto J; Behrens C; Cascone T; Peng W; Kalhor N; Moran CA; Weissferdt A; Johnson FM; William WN; Swisher SG; Lee JJ; Hong WK; Heymach JV; Wistuba II; Futreal PA; Zhang J
Mod Pathol; 2018 Jun; 31(6):947-955. PubMed ID: 29410488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
